An Open, Single Center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-MERS-S
Latest Information Update: 04 Nov 2021
Price :
$35 *
At a glance
- Drugs MVA MERS S (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man; Therapeutic Use
- 28 Apr 2020 New trial record
- 21 Apr 2020 Results published in the German Center for Infection Research media release
- 21 Apr 2020 According to a German Center for Infection Research media release, this trial was conducted in collaboration with the Clinical Trial Center North (CTC North).